| Code | CSB-RA614990MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to CA9hu-1, targeting carbonic anhydrase IX (CA9), a transmembrane metalloenzyme that catalyzes the reversible hydration of carbon dioxide to carbonic acid. CA9 plays a critical role in pH regulation and is characteristically overexpressed in hypoxic tumor microenvironments, particularly in renal cell carcinoma, where it serves as a diagnostic and prognostic biomarker. The enzyme's expression is tightly regulated by hypoxia-inducible factor 1-alpha (HIF-1α), making it virtually absent in most normal tissues but highly upregulated in various solid tumors. This restricted expression pattern has established CA9 as a valuable target for cancer research and therapeutic development.
The reference antibody CA9hu-1 is a well-characterized humanized monoclonal antibody that has been extensively utilized in oncology research for detecting and studying CA9 expression patterns in tumor tissues. This biosimilar provides researchers with a reliable tool for investigating CA9-mediated tumor acidification, hypoxic adaptation mechanisms, and potential therapeutic interventions in cancer biology studies.
There are currently no reviews for this product.